Table 2 Summary of included studies for prognostic biomarkers
Article | Year | Biomarker | Intervention | Significant outcomes |
|---|---|---|---|---|
Sieuwerts et al. [18] | 2019 | ARV | Cabazitaxel | Median OS: 7.7 months (95% CI 7.0–10.6) Median OS (ARV7− vs ARV7+): 9 vs 3.7 months |
Belderbos et al. [19] | 2019 | ARV | Cabazitaxel | Median OS: HR: 1.33, 95% CI 0.81–2.15, p = 0.25 Median OS (ARV7− vs ARV7+): 12.6 vs 12.3 months |
Cattrini et al. [20] | 2019 | ARV | ARAT | Median OS: 4.7 months (95% CI 0.6–8.9) |
Qu et al. [21] | 2014 | ARV | TURP | Time to CRPC: 9.0 months Median follow-up: 25 months Median CSS: 17 months OS (ARV7− vs ARV7+): HR (95% CI), 2.247 (1.066–4.737) 0.033 |
Antonarakis et al. [22] | 2017 | ARV | Abiraterone or enzalutamide | Median follow-up (CTC−, CTC+/AR-V7− and CTC+/AR-V7+): 15.0, 21.7, and 14.6 months Median OS (CTC−, CTC+/AR-V7− and CTC+/AR-V7+): HR (95% CI), 28.7 (28.4 to not reached, 29.5 months (18.4 to not reached), 11.2 months (8.3 to 17.1) Median follow-up: 15.0, 21.7, and 14.6 months Time to CRPC: 23.0, 20.5 and 14.0 months |
Qu et al. [23] | 2017 | ARV | Abiraterone or enzalutamide | Median OS in abiraterone (ARV7− vs ARV7+): 35.6 vs 27.2 month Median OS in enzalutamide (ARV7− vs ARV7+): 29.1 vs 13.8 months Median TTF (abiraterone vs enzalutamide): 10.3 vs 3.7 |
Carles et al. [24] | 2018 | CTC | Radium-223 | Median OS: 16 months Median OS (> 5CTC):16 months Mean follow-up: 9 ± 6 months |
De Kruihiff et al. [25] | 2019 | CTC | Cabazitaxel | Median PFS for CTC < 5 CTC at baseline vs < 5 CTC after treatment: 8.7 months ≥ 5 CTC at baseline vs < 5 CTC after treatment: 6.4 months < 5 CTC at baseline vs ≥ 5 CTC after treatment: 7.4 months ≥ 5 CTC at baseline vs ≥ CTC after treatment: 3.5 months Median OS for CTC < 5 CTC at baseline vs < 5 CTC after treatment: 19 months ≥ 5 CTC at baseline vs < 5 CTC after treatment: 12.8 months < 5 CTC at baseline vs ≥ 5 CTC after treatment: 23 months ≥ 5 CTC at baseline vs ≥ CTC after treatment: 6.9 months |
Bitting et al. [26] | 2015 | CTC | Abiraterone, enzalutamide | Median OS: 11.2 months Median PFS: 4.4 months Median OS (< 5 CTC vs > 5 CTC):16.6 vs 8.9 months Median PFS (< 5 CTC vs > 5 CTC): 5.7 vs 3.7 months |
Josefsson et al. [27] | 2017 | CTC | ADT | Median PFS (CTC+ vs CTC−): 8.5 months Median follow-up: 11.1 months |